Skip to main content
SpringerLink
Log in

63rd Annual Scientific Sessions of the American College of Cardiology: 29–31 March 2014; Washington, DC, USA

  • Meeting Report
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35(9):528–35. doi:10.1002/clc.22008 (Epub 2012 May 9).

    Article  PubMed  Google Scholar 

  2. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. doi:10.1056/NEJMoa1402670 (Epub 2014 Mar 29).

    Article  CAS  PubMed  Google Scholar 

  3. Medtronic, Inc. Medtronic releases results of SYMPLICITY HTN-3 [press release dated 2014 March 29]. Available online from http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1913401&highlight=&utm_source=MDT_com_Symplifybptrial_Home_Page&utm_medium=Impt_Info_ReadPR_Link&utm_campaign=Renal_Denervation_RDN_Press_Release_032914. Accessed 30 Mar 2014.

  4. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs. 2011;11(3):145–52.

    Article  CAS  PubMed  Google Scholar 

  5. Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37(3):131–9. doi:10.1002/clc.22248 (Epub 2014 Jan 29).

    Article  PubMed  Google Scholar 

  6. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 Antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 Clinical Trial of Evolocumab. J Am Coll Cardiol. 2014;63(23):2541–8. doi:10.1016/j.jacc.2014.03.019 (Epub 2014 Mar 30).

    Article  CAS  PubMed  Google Scholar 

  7. Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014;37(4):195–203. doi:10.1002/clc.22252 (Epub 2014 Jan 30).

    Article  PubMed  Google Scholar 

  8. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82. doi:10.1001/jama.2014.4030.

    Article  PubMed  Google Scholar 

  9. Imazio M, Cecchi E, Ierna S, et al. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials—two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown). 2007;8(10):830–4.

    Article  Google Scholar 

  10. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7. doi:10.1016/S0140-6736(13)62709-9 (Epub 2014 Mar 30).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The author has no potential conflict of interest that might be relevant to the contents of this manuscript. The author would like to thank the American College of Cardiology for the opportunity to attend this congress.

Author information

Authors and Affiliations

  1. Adis, Auckland, New Zealand

    Amitabh Prakash

Authors
  1. Amitabh Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amitabh Prakash.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prakash, A. 63rd Annual Scientific Sessions of the American College of Cardiology: 29–31 March 2014; Washington, DC, USA. Am J Cardiovasc Drugs 14, 327–331 (2014). https://doi.org/10.1007/s40256-014-0086-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-014-0086-z

Keywords

Search

Navigation